
Article:
Daniel, E. orcid.org/0000-0003-4699-420X, Aylwin, S., Mustafa, O. et al. (25 more authors) (2015) Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 100 (11). pp. 4146-4154. ISSN 0021-972X

https://doi.org/10.1210/jc.2015-2616

Published in final edited form as:
J Clin Endocrinol Metab. 2015 November ; 100(11): 4146–4154. doi:10.1210/jc.2015-2616.

Effectiveness of Metyrapone in Treating Cushing' s Syndrome: A Retrospective Multicenter Study in 195 Patients

Eleni Daniel,
The Medical School, University of Sheffield, S10 2RX Sheffield, United Kingdom

Simon Aylwin,
King' s College Hospital NHS Foundation Trust, B15 2TT London, United Kingdom

Omar Mustafa,
King' s College Hospital NHS Foundation Trust, B15 2TT London, United Kingdom

Steve Ball,
The Medical School, Newcastle University, NE2 4HH Newcastle, United Kingdom; Royal Victoria Infirmary, SE5 9RS Newcastle, United Kingdom

Atif Munir,
Royal Victoria Infirmary, SE5 9RS Newcastle, United Kingdom

Kristien Boelaert,
College of Medical and Dental Sciences, Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, M13 9PT Birmingham, United Kingdom

Vasileios Chortis,
College of Medical and Dental Sciences, Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, M13 9PT Birmingham, United Kingdom

Daniel J. Cuthbertson,
Department of Obesity and Endocrinology, University of Liverpool, NE1 4LP Liverpool, United Kingdom

Christina Daousi,
Department of Obesity and Endocrinology, University of Liverpool, NE1 4LP Liverpool, United Kingdom

Surya P. Rajeev,
Department of Obesity and Endocrinology, University of Liverpool, NE1 4LP Liverpool, United Kingdom

Julian Davis,

Address all correspondence and requests for reprints to: John Newell-Price, MA, PhD, FRCP, Professor of Endocrinology, Department of Human Metabolism, Medical School, University of Sheffield, Beech Hill Road, Sheffield S10 2RX, United Kingdom. j.newellprice@sheffield.ac.uk.

Disclosure Summary: E.D., S.A., K.B., D.J.C., W.D., A.G., N.K., T.K., and K.Me. have previously consulted for HRA Pharma; A.R., M.G., and J.N.-P. have consulted for HRA Pharma and Novartis; and O.M., S.B., A.M., V.C., C.D., S.P.R., J.D., K.C., K.G., A.S.P., I.H., K.Mo., N.H., A.J.L., P.J.T., and A.-E.H.M. have nothing to declare.

Europe PMC Funders Author Manuscripts

Centre for Endocrinology and Diabetes, University of Manchester, L69 3GA Manchester, United Kingdom

Kelly Cheer,
Manchester Royal Infirmary, M13 9WL Manchester, United Kingdom

William Drake,
Department of Endocrinology, St Bartholomew' s Hospital, EC1A 7BE London, United Kingdom

Kirun Gunganah,
Department of Endocrinology, St Bartholomew' s Hospital, EC1A 7BE London, United Kingdom

Ashley Grossman,
Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, M6 8HD Oxford, United Kingdom

Mark Gurnell,
Wellcome Trust–MRC Institute of Metabolic Science, University of Cambridge, Addenbrooke' s Hospital, OX3 7LE Cambridge, United Kingdom

Andrew S. Powlson,
Wellcome Trust–MRC Institute of Metabolic Science, University of Cambridge, Addenbrooke' s Hospital, OX3 7LE Cambridge, United Kingdom

Niki Karavitaki,
College of Medical and Dental Sciences, Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, M13 9PT Birmingham, United Kingdom; Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, M6 8HD Oxford, United Kingdom

Isabel Huguet,
Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, M6 8HD Oxford, United Kingdom

Tara Kearney,
Salford Royal Foundation Trust, CB2 0QQ Salford, United Kingdom

Kumar Mohit,
Salford Royal Foundation Trust, CB2 0QQ Salford, United Kingdom

Karim Meeran,
Imperial College, SW7 2AZ London, United Kingdom

Neil Hill,
Imperial College, SW7 2AZ London, United Kingdom

Aled Rees,
School of Medicine, Cardiff University, CF14 4XN Cardiff, United Kingdom

Andrew J. Lansdown,
School of Medicine, Cardiff University, CF14 4XN Cardiff, United Kingdom

Peter J. Trainer,
The Christie NHS Foundation Trust, M20 4BX Manchester, United Kingdom

Europe PMC Funders Author Manuscripts

Anna-Elisabeth H. Minder, and
The Christie NHS Foundation Trust, M20 4BX Manchester, United Kingdom

John Newell-Price
The Medical School, University of Sheffield, S10 2RX Sheffield, United Kingdom

Europe PMC Funders Author Manuscripts

Abstract

Background—Cushing's syndrome (CS) is a severe condition with excess mortality and significant morbidity necessitating control of hypercortisolemia. There are few data documenting use of the steroidogenesis inhibitor metyrapone for this purpose.

Objective—The objective was to assess the effectiveness of metyrapone in controlling cortisol excess in a contemporary series of patients with CS.

Design—This was designed as a retrospective, multicenter study.

Setting—Thirteen University hospitals were studied.

Patients—We studied a total of 195 patients with proven CS: 115 Cushing's disease, 37 ectopic ACTH syndrome, 43 ACTH-independent disease (adrenocortical carcinoma 10, adrenal adenoma 30, and ACTH-independent adrenal hyperplasia 3).

Measurements—Measurements included biochemical parameters of activity of CS: mean serum cortisol "day-curve" (CDC) (target 150 –300 nmol/L); 9 AM serum cortisol; 24-hour urinary free cortisol (UFC).

Results—A total of 164/195 received metyrapone monotherapy. Mean age was 49.6 ± 15.7 years; mean duration of therapy 8 months (median 3 mo, range 3 d to 11.6 y). There were significant improvements on metyrapone, first evaluation to last review: CDC (91 patients, 722.9 nmol/L [26.2 μg/dL] vs 348.6 nmol/L [12.6 μg/dL]; $P < .0001$); 9 AM cortisol (123 patients, 882.9 nmol/L [32.0 μg/dL] vs 491.1 nmol/L [17.8 μg/dL]; $P < .0001$); and UFC (37 patients, 1483 nmol/24 h [537 μg/24 h] vs 452.6 nmol/24 h [164 μg/24 h]; $P = .003$). Overall, control at last review: 55%, 43%, 46%, and 76% of patients who had CDCs, UFCs, 9 AM cortisol less than 331 nmol/L (12.0 μg/dL), and 9 AM cortisol less than upper limit of normal/600 nmol/L (21.7 μg/dL). Median final dose: Cushing's disease 1375 mg; ectopic ACTH syndrome 1500 mg; benign adrenal disease 750 mg; and adrenocortical carcinoma 1250 mg. Adverse events occurred in 25% of patients, mostly mild gastrointestinal upset and dizziness, usually within 2 weeks of initiation or dose increase, all reversible.

Conclusions—Metyrapone is effective therapy for short- and long-term control of hypercortisolemia in CS.

Cushing's syndrome (CS) is a severe condition with excess mortality and significant morbidity necessitating effective biochemical control (1). Where a cause amenable to surgical intervention is identified, surgery at a center with appropriate expertise is the optimum management. Nevertheless, many patients need urgent control of severe or persisting hypercortisolemia. Options for medical treatment include steroidogenesis enzyme inhibitors suitable for all causes of CS (ketoconazole, metyrapone, mitotane), agents to suppress ACTH in Cushing's disease (CD), such as dopamine agonists and pasireotide, and

the glucocorticoid receptor antagonist, mifepristone (2, 3). The modern use of ketoconazole has recently been reported in a multicenter French Study (4), although its availability in the United States has been restricted after an Food and Drug Administration safety warning for hepatotoxicity in 2013 (5, 6), but it is widely available in Europe in 2015 (7).

The cortisol-lowering effect of metyrapone was described as early as 1958 by Liddle et al (8), with later reports confirming metyrapone as a potent inhibitor of the steroidogenesis enzyme 11β-hydroxylase (8, 9). Since then, it has been used as a diagnostic test of adrenal reserve and to treat the hypercortisolism of CS. Despite its wide-spread use, data on metyrapone are scarce, with the largest study to date (including 91 patients) being published over 25 years ago (10). Here, we have assessed the effectiveness of metyrapone therapy in a contemporary series of patients with CS, by performing a retrospective study of patients treated in the United Kingdom.

Materials and Methods

A multicenter, retrospective study was performed across 13 University hospital centers in England and Wales, members of the United Kingdom Endocrine Neoplasia Collaboration. Patients treated with metyrapone were identified through pharmacy records and electronic databases. Patients with a diagnosis of CS and treated with metyrapone between 1997 and 2013 were included.

The same proforma was used in all centers to record anonymized data. Data were gathered from case records and electronic record systems. Baseline, demographic and safety data, the indication for treatment and dose of metyrapone therapy, any therapeutic intervention and any recorded adverse events were documented. Monitoring tests included early morning (9 AM) serum cortisol, 24-hour urinary free cortisol (UFC), serum potassium, plasma ACTH, and serum cortisol “day-curves” (CDCs). In CDCs multiple samples for serum cortisol are collected across the day with the mean calculated (11). The majority (91%) of CDCs consisted of 4 or 5 serum cortisol samples (minimum 3, maximum 8, median 4). All tests performed during the monitoring period were collected and analyzed. All centers used immunoassay-based cortisol assays.

Patients were treated either with a dose titration regimen, ie, metyrapone dose was up-titrated according to response to achieve a biochemical target for cortisol, or a block-and-replace regimen, where the dose of metyrapone was quickly up-titrated to achieve blockade of cortisol synthesis and a replacement dose of glucocorticoid was added to provide background physiological levels.

Biochemical targets for treatment (eucortisolemia) were defined as a mean CDC value of 150–300 nmol/L (10.9 μg/dL), which has been shown to equate to a normal cortisol production rate as assessed by stable isotopic methodology (11), a UFC level below the upper limit of normal (ULN) for the assay used or a 9 AM serum cortisol within target. Although 9 AM serum cortisol is occasionally being used as a sole test for evaluating patients’ response to treatment, there is currently no standardized agreement for what values of this test represent appropriate control. Two different levels of target 9 AM cortisol were

therefore assessed: 1) below the ULN for the assay used, or less than 600 nmol/L (21.7 μg/dL) if the ULN was higher than this value; and 2) a recommended value of 331 nmol (12.0 μg/dL) (12). Cortisol levels were reported in nmol/L and divided by 27.59 to calculate the equivalent value in μg/dL. There was a wide range of UFC assays used with variable reference range of normal values; therefore, UFC values were converted to multiples of the ULN for the assay and this value was used for statistical comparisons. Patients with sufficient monitoring data (ie, at least one test as described above repeated at least twice during the study period) were included in the efficacy analysis. For the efficacy analyses we compared the mean values at each monitoring test (CDC, 9 AM serum cortisol, UFC) before treatment with 1) the mean values on the last review on treatment (diagnosis vs last review); and 2) the mean of all tests performed in all patients during treatment (diagnosis vs treatment), unless otherwise stated. The change of the biochemical markers between 1) baseline (at diagnosis/pretreatment) and the last review on treatment for 9 AM cortisol; and 2) the first and the last biochemical review for CDCs (CDCs were not routinely performed before initiation of treatment) on treatment was also analyzed.

Statistical analysis was performed using the 2-tailed Student's *t* test (GraphPad prism 6.0; GraphPad Software, Inc). Except where stated, values given are means ± SDs. $P < .05$ was considered significant. The study was approved as an institutional case notes review at each participating center.

Results

Baseline characteristics

A total of 195 patients were treated with metyrapone across the 13 centers. Most patients had CD (115 patients, 37 macroadenoma) with the remainder having ectopic ACTH syndrome (EAS) (37), adrenocortical carcinoma (ACC) (10), and benign adrenal disease (30 adrenal adenoma [AA], ACTH-independent macronodular adrenal hyperplasia [2] and primary pigmented nodular adrenal hyperplasia [1]) (Table 1). There was a female predominance in all causes of CS except EAS (female patients:74% CD, 49% EAS, 86% AA, and 80% ACC). Patients were treated with metyrapone between 1997 and 2013 (83% between 2007 and 2013). The average duration of treatment was 8 months (median 3 mo, range 3 d to 11.6 y). At initiation of treatment, there was a wide age distribution, with 76% of patients aged 30–69 years (age range 1–81, median age 48, average age 49.6 ± 15.7 y), and 32% of patients (n = 63) were women in the reproductive ages 18–45 (Figure 1). Comorbidities at presentation included hypertension (64.6%) and diabetes mellitus (35.3%). For patients with CD, baseline contrast-enhanced pituitary magnetic resonance imaging was positive in all patients with a macroadenoma and in 53 out of 72 (73%) patients with a microadenoma.

The main indication for metyrapone therapy was the control of severe symptoms of CS (CD 58%, EAS 77%, benign adrenal disease 44% and ACC 80%). Medical therapy was initiated as part of routine local practice in 8 out of 13 centers for the management of patients after diagnosis and before definitive therapy (eg, surgery) regardless of the level of hypercortisolemia in a smaller number of patients (CD 25%, EAS 11%, benign adrenal disease 37%, ACC 0%). Delay in definitive treatment for CS (either due to medical reasons

Europe PMC Funders Author Manuscripts

or requested by the patient) was a reason for starting medical therapy in 19% of patients. A total of 25/195 patients (12.8%) received only cortisol-lowering treatment for their CS because of either inconclusive surgical target, palliation of aggressive malignancy (ACC or lung carcinoma), patients' own preference, or high surgical risk.

Biochemical changes during metyrapone treatment

Monitoring data during metyrapone therapy were available for 193 patients. The frequency of the monitoring visits was variable with some centers opting for inpatient tests at the introduction of treatment and other centers using outpatient monitoring every few weeks; 81% of patients were treated with dose titration and 19% with "block-and-replace."

Metyrapone monotherapy

A total of 164 patients received metyrapone monotherapy, and all monitoring tests showed significant improvement during treatment (Table 2). At the last review, 55%, 43%, 46%, and 76% of patients who had CDCs, UFCs, 9 AM cortisol less than 331 nmol/L (12.0 μg/dL), and 9 AM cortisol less than ULN/600 nmol/L (21.7 μg/dL) were controlled.

Ninety-one patients were monitored with CDCs during treatment; 47/91 (52%) patients achieved a mean CDC less than 300 nmol/L (10.9 μg/dL) during treatment (ie, normalized cortisol target) and 81% of those who did not normalize had an improvement between the first and the last assessment on treatment (Figure 2A). Patients on a block-and replace regimen were more likely to achieve have a mean CDC less than 150 nmol/L. A total of 123 patients had 9 AM serum cortisol levels monitored; during treatment 83% (102/123) had a 9 AM serum cortisol bellow 600 nmol/L (21.7 μg/dL) or the ULN for the assay used and 56% (69/123) had a 9 AM level below 331 nmol/L (12.0 μg/dL) with 86% of patients showing an improvement in cortisol levels (mean improvement 566 nmol/L, median 467 nmol/L) even if these biochemical targets were not achieved (Figure 2B).

Effectiveness of metyrapone monotherapy before surgery

The majority (124/164) of patients treated with metyrapone monotherapy received treatment before any surgical intervention (CD 81, EAS 11, benign adrenal disease 25, ACC 7) for an average of 4.0 months. There was a significant improvement in the biochemical targets during metyrapone therapy (Table 2). At the last review, 50%, 35%, 40%, or 72% of patients who had CDCs, UFCs, 9 AM cortisol less than 331 nmol/L (12 μg/dL), or 9 AM cortisol less than ULN/600 nmol/L (21.7 μg/dL) were controlled (for dose see Table 3).

At the time of the first normalization, 91% were treated with dose titration and 9% with block-and-replace. In ACTH-dependent disease, plasma ACTH levels were measured too sporadically to allow meaningful analysis. A total of 10/18 (56%) patients who did not achieve a biochemical target also had a reduction of cortisol levels.

Metyrapone monotherapy as secondary treatment

Thirty-one patients (29 CD, 1 EAS, 1 benign adrenal disease) received metyrapone as secondary treatment after either surgery (21) or pituitary radiotherapy (17): 21/31 as monotherapy and 10/31 as combination therapy. Of the patients who received metyrapone

Europe PMC Funders Author Manuscripts

after primary surgery, 19 had pituitary surgery for CD (9 had a macroadenoma), 1 had a pancreatectomy for a neuroendocrine tumor, and 1 a repeat adrenalectomy for an incomplete excision of an AA. Of the patients with CD, 7/19 also received pituitary radiotherapy. For the patients on monotherapy (n = 21), the mean starting dose of metyrapone was 1300 mg (Table 3). Patients were treated for an average of 17.1 months. At the last review, 76%, 78%, or 94% of patients who had CDCs, 9 AM cortisol less than 331 nmol/L (12 μg/dL) or 9 AM cortisol less than ULN/600 nmol/L (21.7 μg/dL) were controlled. At normalization, 35% (6/17) of patients were treated with block-and-replace and 65% (11/17) with dose titration. Biochemical tests (mean CDC and 9 AM cortisol) improved during treatment (Table 2). Only 4 patients had UFCs during treatment, therefore the change in UFC for this group of patients was not analyzed.

Long-term treatment with metyrapone monotherapy

Monitoring data were available on 38 patients who received metyrapone monotherapy for longer than 6 months. The average duration of treatment was 18.6 months, and 6 patients had block-and-replace at some point during their treatment. Biochemical tests improved during treatment (Table 2). Overall, eucortisolemia was achieved in 72% (18/25) of patients who had CDCs, 77% (24/31) and 94% (29/31) of patients who had 9 AM cortisols (based on <331 nmol/L or <ULN/600 nmol/L cut-offs) or 64% (9/14) of patients who had UFCs.

Starting and final dose (Table 3)

Mean, median, and range of doses on metyrapone monotherapy at the initiation of treatment and at final review are shown in Table 3. On block-and-replace the starting dose of metyrapone was higher (mean dose 1432 mg vs 939.2 mg, $P < .0001$). There were, however, no significant differences in the mean 9 AM serum cortisol levels during treatment or at the last review in the 2 groups (block-and-replace group during treatment 461.2 nmol/L [16.7 μg/dL] vs dose titration group 507.8 nmol/L [18.4 μg/dL]; $P = .50$, last review 510.8 nmol/L [18.5 μg/dL] vs 376.3 nmol/L [13.6 μg/dL]; $P = .26$).

Combination treatment

Twenty-nine patients were treated with a combination of metyrapone and other cortisol-lowering medication (mainly ketoconazole or mitotane, 7 patients had combination treatment from the start of therapy, whereas in 22, combination therapy was instigated after initial treatment with metyrapone). The CDC or 9 AM serum cortisol levels at diagnosis were not significantly different in the patients treated with combination compared with the patients treated with metyrapone monotherapy (CDC combination 830.8 nmol/L [30.1 μg/dL] vs monotherapy 722.9 nmol/L [26.2 μg/dL]; $P = .558$, and 9 AM cortisol, combination 1149 nmol/L [41.6 μg/dL], vs monotherapy 882.9 nmol/L [32.0 μg/dL]; $P = .077$). There was a significant improvement in CDC and 9 AM serum cortisol during treatment (Table 2). Only 3 patients on combination therapy had UFC monitoring, pre-cluding analysis. At the last review, 47%, 52%, or 75% of patients who had CDCs, 9 AM cortisol less than 331 nmol/L (12 μg/dL), or 9 AM cortisol less than ULN/600 nmol/L (21.7 μg/dL) were controlled. Patients who at the last review were controlled on a dose titration regimen based on CDCs and UFCs received 1850-mg mean total daily dose (median 1500 mg, range 750–

Europe PMC Funders Author Manuscripts

6000 mg). No subgroup analysis for efficacy was performed for this group due to small numbers.

Safety considerations

Side effects were noted in 48/195 patients (25%): 88% were managed as outpatients, whereas 12% (7/57 events) required either admission for evaluation or prolongation of a current admission. The rate of adverse events in patients on therapy for more than 6 months was 11% (4/38 patients). There were no pregnant women and no deaths recorded due to an adverse event. The average dose of metyrapone at the time of an adverse event was 1600 mg. Gastrointestinal (GI) upset (23%) and hypoadrenalism (7%, symptoms of dizziness, hypotension, with biochemical confirmation) were the most common side effects. Most adverse events (39/56) occurred within 15 days of initiation of metyrapone or after a dose increase. GI upset and dizziness were the main reasons for discontinuing treatment. Patients with confirmed hypoadrenalism were managed either by addition of glucocorticoid (regimen change to a block-and-replace) or temporary cover with glucocorticoid and simultaneous reduction of metyrapone dose. In 15% of cases, the metyrapone dose was reduced. In 12 cases (23%), metyrapone was withdrawn temporarily or permanently, with 11/12 showing full resolution, and in 1, symptoms continued but became less severe, muscle aches at presentation worsened during metyrapone therapy but returned to pretreatment levels after drug withdrawal. Symptoms of hyperandrogenism were not frequent; hirsutism was not reported, and there was only 1 case of worsening acne during treatment. Similarly, edema was only reported in 1 case, but the causative drug was thought to be a calcium channel blocker. Hypoglycemia was reported in 3 patients on diabetic medications and was associated with improvement of hypercortisolism.

Potassium levels were monitored and actively treated at presentation and during therapy. In 138 patients on metyrapone monotherapy, with no other treatment interventions for their CS, mean potassium levels increased from 3.68 to 3.90 nmol/L ($P = .003$) during treatment (Figure 3).

Discussion

We report the effectiveness of metyrapone in clinical practice for the treatment of CS. To our knowledge, this is the largest study of metyrapone use as either monotherapy or metyrapone in combination with other cortisol-lowering medications. Overall, more than 80% of patients showed an improvement in levels of circulating cortisol with over 50% achieving biochemical eucortisolemia when on monotherapy when assessed by the stringent criterion of control on a CDC. It is likely that additional therapies were added because of the severity of disease and clinician preference, but the retrospective and multicenter nature of our study precludes a formal assessment of this. Furthermore, our data support that metyrapone monotherapy is an effective treatment for hypercortisolemia either before or after surgical intervention to the primary cause of CS.

Metyrapone is widely used in CS in the United Kingdom and other countries but less so in the United States. To date, the efficacy of metyrapone in reducing cortisol levels in CS has been described in case reports and small case series (13–16), with the largest series reported

25 years ago by Verhelst et al (10). In this single center experience, metyrapone was effective in reducing cortisol levels in 75% of 91 patients with CD, EAS, and ACC based on a mean CDC level less than 400 nmol/L that is higher than the more stringent less than 300 nmol/L level that we used in this study. Most patients in the Verhelst study received a short course of metyrapone except for 24 patients who had metyrapone for a median of 27 months after radiotherapy to the pituitary gland. Smaller studies have reported the efficacy of metyrapone in patients with CD undergoing radiotherapy (13–15) and EAS (17). Overall, in 200 cases of metyrapone monotherapy published in the English literature, biochemical control was achieved in 75% (18). We report similar efficacy. It is of note, however, that most patients with CD in our study here were not treated in conjunction with pituitary radiotherapy, and there did not appear to be evidence of an escape of control phenomenon, although we cannot comment on plasma ACTH levels during monitoring.

Ketoconazole, an antifungal agent and inhibitor of adrenal steroidogenesis, has also been widely used as a cortisol-lowering agent in CS. In the largest report to date, Castinetti et al reported biochemical control in 50% of patients with CS treated with ketoconazole monotherapy with biochemical improvement in 75% and evidence of regression of clinical features in up to 60% (4). Overall, in 456 published cases treated with ketoconazole monotherapy, 60% achieved control (18). Combination treatment with metyrapone and ketoconazole is commonly used (19), especially for the rapid control of hypercortisolism before definite treatment. In 22 patients with severe hypercortisolism due to EAS (n = 14) and ACC (n = 8), combination treatment of metyrapone and ketoconazole dramatically improved UFC levels within a month of treatment, whereas half of the patients also started mitotane during this time (20). Kamenický et al (21) used a triple-medication protocol with simultaneous administration of ketoconazole, metyrapone and mitotane in 11 patients with hypercortisolism and life-threatening complications as an alternative to bilateral adrenalectomy; all patients showed rapid clinical and biochemical improvement. In both studies, the initial biochemical control is mainly due to the combination of ketoconazole and metyrapone as the onset of action of mitotane is usually delayed by several weeks due to accumulation in adipose tissue (22). In 1 of the few prospective studies of medical treatment of CD, Feelders et al (23) used a stepwise approach to treat 17 patients with CD with a combination of pituitary and adrenal-acting agents. Patients were initially treated with the somatostatin analog pasireotide, followed by cabergoline, and ketoconazole was later introduced if biochemical control was suboptimal. Nine out of 17 patients normalized with pasireotide/cabergoline and ketoconazole induced biochemical control in 6/8 remaining patients (75%) within 20 days of treatment (23).

Metyrapone increases cortisol metabolites in the serum and urine due to the predominant inhibition of 11β-hydroxylase, and to a lesser extent the other steroidogenesis enzymes (10, 24). In particular, 11-deoxycortisol levels may become profoundly elevated in patients on metyrapone therapy, especially in patients with CD (25, 26). 11-deoxycortisol is structurally very similar to cortisol and may cross-react with cortisol immunoassays resulting in an overestimation of serum cortisol values in patients on metyrapone (26). The importance of this is underscored by the fact that symptoms of adrenal insufficiency may overlap those of side effects of metyrapone. Thus, cortisol estimation by more accurate methods such as mass spectrometry is advisable, and should be used where available (27). Moreover, it is likely

that our data may underestimate the efficacy of metyrapone therapy when assessing serum measurements of cortisol as the cross-reactivity in immunoassays results in approximately 20% elevated bias (25).

Hypokalemia has been described as a potential serious complication of metyrapone therapy (24, 28) due to the increase in steroid precursors with mineralocorticoid activity (11-deoxycorticosterone). Our data suggest that clinicians using metyrapone are well aware of the importance of monitoring and managing serum potassium levels, because we found that these increase significantly with supportive measures during treatment. It is important to stress, however, that such active monitoring is required, because hypokalemia is also a potentially harmful feature of CS. The most common adverse effects observed were mild GI symptoms and hypoadrenalism, the latter a positive response to treatment provided that it is recognized and managed early. Patients on long-term treatment are more likely those who tolerate metyrapone well, therefore the rate of adverse events was favorable in this subgroup. Interestingly, hirsutism was not reported.

This study carries the limitations imposed by its retrospective design. Furthermore, there is currently no standardized monitoring and dosing regimen for patients on metyrapone therapy. The monitoring of hypercortisolemia in patients with CS on medical treatment is important to ensure that patients are treated with the correct dose and that hypoadrenalism, if present, is recognized early; measurement of serum cortisol allows this. Even though the study was conducted in University centers with significant expertise in the management of CS, the choice of biochemical monitoring test and frequency of monitoring varied. This has affected the uniformity of the data presented. During the period of the study, the common clinical practice was to aim for a 9 AM cortisol bellow the ULN for the assay used or less than 600 nmol/L. Any results above these levels would prompt up-titration of the dose or addition of a second agent. Therefore, we have reported these cut-offs as the criteria for normalization of hypercortisolemia. More stringent 9 AM serum cortisol levels to define control have been proposed recently (12), with suggested values below 331 nmol/L (12 μg/dL). It is not possible to know whether clinicians would have up-titrated the dose of metyrapone had this criterion been used, and therefore, we can only speculate that the overall control when using this criterion might have been better if applied in practice.

In conclusion, our data show that metyrapone is effective and safe in treating hypercortisolemia in patients with CS.

Acknowledgments

We thank the staff at all centers involved in the care of the patients.

This work was supported in part by an unrestricted grant from HRA Pharma. The Endocrine Neoplasia Collaboration is supported by the Society for Endocrinology and the National Office of Clinical Research Infrastructure of the National Institute for Health Research.

Abbreviations

AA	adrenal adenoma

Europe PMC Funders Author Manuscripts

ACC	adrenocortical carcinoma
CD	Cushing' s disease
CDC	cortisol "day-curve"
CS	Cushing' s syndrome
EAS	ectopic ACTH syndrome
UFC	urinary free cortisol
ULN	upper limit of normal

References

1. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing' s syndrome. Lancet. 2006; 367:1605–1617. [PubMed: 16698415]
2. Basina M, Liu H, Hoffman AR, Feldman D. Successful long-term treatment of Cushing disease with mifepristone (RU486). Endocr Pract. 2012; 18:e114–e120. [PubMed: 22441000]
3. Nieman LK. Medical therapy of Cushing' s disease. Pituitary. 2002; 5:77–82. [PubMed: 12675504]
4. Castinetti F, Guignat L, Giraud P, et al. Ketoconazole in Cushing' s disease: is it worth a try? J Clin Endocrinol Metab. 2014; 99:1623–1630. [PubMed: 24471573]
5. United States Food and Drug Administration. FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. 2013. http://www.fda.gov/Drugs/DrugSafety/ucm362415.htm
6. Trainer PJ. Next generation medical therapy for Cushing' s syndrome–can we measure a benefit? J Clin Endocrinol Metab. 2014; 99:1157–1160. [PubMed: 24702012]
7. European Medicines Agency. Recommendation for maintenance of orphan designation at the time of marketing authorisation: ketoconazole HRA (ketoconazole) for the treatment of Cushing' s syndrome. 2015. http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_review/2015/01/WC500181644.pdf
8. Liddle GW, Island D, Lance EM, Harris AP. Alterations of adrenal steroid patterns in man resulting from treatment with a chemical inhibitor of 11 β-hydroxylation. J Clin Endocrinol Metab. 1958; 18:906–912. [PubMed: 13563620]
9. Sonino N, Chow D, Levine LS, New MI. Clinical response to metyrapone as indicated by measurement of mineralocorticoids and glucocorticoids in normal children. Clin Endocrinol (Oxf). 1981; 14:31–39. [PubMed: 7226574]
10. Verhelst JA, Trainer PJ, Howlett TA, et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing' s syndrome. Clin Endocrinol (Oxf). 1991; 35:169–178. [PubMed: 1657460]
11. Trainer PJ, Eastment C, Grossman AB, Wheeler MJ, Perry L, Besser GM. The relationship between cortisol production rate and serial serum cortisol estimation in patients on medical therapy for Cushing' s syndrome. Clin Endocrinol (Oxf). 1993; 39:441–443. [PubMed: 8287570]
12. Nieman LK. Medical therapy of hypercortisolism (Cushing' s syndrome). UpToDate. 2014 [Accessed May 19, 2015] Updated September 24.
13. Jeffcoate WJ, Silverstone JT, Edwards CR, Besser GM. Psychiatric manifestations of Cushing' s syndrome: response to lowering of plasma cortisol. Q J Med. 1979; 48:465–472. [PubMed: 542586]
14. Jeffcoate WJ, Rees LH, Tomlin S, Jones AE, Edwards CR, Besser GM. Metyrapone in long-term management of Cushing' s disease. Br Med J. 1977; 2:215–217. [PubMed: 195666]

15. Ross WM, Evered DC, Hunter P, Benaim M, Cook D, Hall R. Treatment of Cushing' s disease with adrenal blocking drugs and megavoltage therapy to the pituitary. Clin Radiol. 1979; 30:149–153. [PubMed: 219982]
16. Child DF, Burke CW, Burley DM, Rees LH, Fraser TR. Drug controlled of Cushing' s syndrome. Combined aminoglutethimide and metyrapone therapy. Acta Endocrinol (Copenh). 1976; 82:330–341. [PubMed: 179256]
17. Doi M, Sugiyama T, Izumiyama H, Yoshimoto T, Hirata Y. Clinical features and management of ectopic ACTH syndrome at a single institute in Japan. Endocr J. 2010; 57:1061–1069. [PubMed: 21076235]
18. Daniel E, Newell-Price JD. Therapy of endocrine disease: steroidogenesis enzyme inhibitors in Cushing' s syndrome. Eur J Endocrinol. 2015; 172:R263–R280. [PubMed: 25637072]
19. Valassi E, Crespo I, Gich I, Rodriguez J, Webb SM. A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing' s syndrome. Clin Endocrinol (Oxf). 2012; 77:735–742. [PubMed: 22533782]
20. Corcuff JB, Young J, Masquefa-Giraud P, Chanson P, Baudin E, Tabarin A. Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole. Eur J Endocrinol. 2015; 172:473–481. [PubMed: 25624013]
21. Kamenický P, Droumaguet C, Salenave S, et al. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing' s syndrome. J Clin Endocrinol Metab. 2011; 96:2796–2804. [PubMed: 21752886]
22. Touitou Y, Moolenaar AJ, Bogdan A, Auzéby A, Luton JP. o,p' -DDD (mitotane) treatment for Cushing' s syndrome: adrenal drug concentration and inhibition in vitro of steroid synthesis. Eur J Clin Pharmacol. 1985; 29:483–487. [PubMed: 4092727]
23. Feelders RA, de Bruin C, Pereira AM, et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing' s disease. N Engl J Med. 2010; 362:1846–1848. [PubMed: 20463350]
24. Coppage WS Jr, Island D, Smith M, Liddle GW. Inhibition of aldosterone secretion and modification of electrolyte excretion in man by a chemical inhibitor of 11 β-hydroxylation. J Clin Invest. 1959; 38:2101–2110. [PubMed: 13811859]
25. Monaghan PJ, Owen LJ, Trainer PJ, Brabant G, Keevil BG, Darby D. Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11β-hydroxylase inhibitor metyrapone. Ann Clin Biochem. 2011; 48:441–446. [PubMed: 21813575]
26. Owen LJ, Halsall DJ, Keevil BG. Cortisol measurement in patients receiving metyrapone therapy. Ann Clin Biochem. 2010; 47:573–575. [PubMed: 20926474]
27. Monaghan PJ, Keevil BG, Trainer PJ. The use of mass spectrometry to improve the diagnosis and the management of the HPA axis. Rev Endocr Metab Disord. 2013; 14:143–157. [PubMed: 23494459]
28. Feelders RA, Hofland LJ. Medical treatment of Cushing' s disease. J Clin Endocrinol Metab. 2013; 98:425–438. [PubMed: 23345100]



Figure 1.
Age of patients at initiation of metyrapone therapy and diagnosis of CS.

Europe PMC Funders Author Manuscripts

Europe PMC Funders Author Manuscripts



Figure 2.

Mean serum CDC and 9 AM serum cortisol levels during treatment with metyrapone monotherapy. A, Change in mean CDC in 91 patients treated with metyrapone monotherapy between the first review after initiation of metyrapone and the last review on treatment: 52% (47/91) patients achieved biochemical normalization, 89% showed an improvement. B, Change in the pretreatment 9 AM cortisol level in 123 patients treated with metyrapone monotherapy and the last review on treatment: 86% showed an improvement; 102 (83%)

patients had a 9 AM serum cortisol value below the ULN for the assay used or 600 nmol/L (whichever was lowest) and 69 (56%) had a 9 AM level less than 331 nmol/L.

Europe PMC Funders Author Manuscripts

Europe PMC Funders Author Manuscripts



Figure 3.
Potassium levels before and during metyrapone monotherapy in 138 patients.

Europe PMC Funders Author Manuscripts

Table 1

Baseline Patient Characteristics

Etiology	Number of Patients	Female/Male	Average Age at Diagnosis (y)	Average Age at Metyrapone Onset (y)
CD	115[a]	85/30	45.9	47.4
Macroadenoma	37			
Microadenoma	77			
EAS	37	18/19	52.6	52.9
Benign adrenal disease	33	27/6	50.3	51.2
AA	30	26/4		
AIMH	2	1/1		
PPNAD	1	0/1		
ACC	10	8/2	56.0	56.4

Abbreviations: AIMH, ACTH-independent macronodular hyperplasia; PPNAD, primary pigmented nodular adrenal disease.

[a]Size of adenoma not available in 1 patient.

Table 2

Change in Biochemical Markers During Metyrapone Therapy (Mean Values)

	Number of Patients	Pretreatment	During Treatment[a]	At the Last Review on Treatment[a]
Monotherapy				
Overall	164			
Mean CDC[b]	91	722.9 nmol/L (26.2 μg/dL)	396.4 nmol/L (14.4 μg/dL), $P < .0001$	348.6 nmol/L (12.6 μg/dL), $P < .0001$
9 AM serum cortisol	123	882.9 nmol/L (32.0 μg/dL)	527.8 nmol/L (19.1 μg/dL), $P < .0001$	491.1 nmol/L (17.8 μg/dL), $P < .0001$
UFC	37	1483 nmol/24 h (537 μg/24 h)	1070 nmol/24 h (388 μg/24 h), $P = .588$	453 nmol/24 h (164 μg/24 h), $P = .003$
UFC:ULN[c]	37	7.2	5.4, $P = .556$	2.5, $P = .020$
Before surgery	124			
Mean CDC	70	691.5 nmol/L (25.1 μg/dL)	407.7 nmol/L (14.8 μg/dL), $P < .0001$	351.5 nmol/L (12.7 μg/dL), $P < .0001$
9 AM serum cortisol	82	779.7 nmol/L (28.3 μg/dL)	508.0 nmol/L (18.4 μg/dL), $P < .0001$	495.6 nmol/L (18.0 μg/dL), $P < .0001$
UFC	25	1318 nmol/24 h (478 μg/24 h)	1049 nmol/24 h (380 μg/24 h), $P = .704$	525 nmol/24h (190 μg/24 h), $P = .008$
UFC:ULN	25	6.4	5.5, $P = .553$	2.9, $P = .014$
Secondary therapy	21			
Mean CDC	12	478.5 nmol/L (17.3 μg/dL)	311.0 nmol/L (11.3 μg/dL), $P = .001$	248.9 nmol/L (9.0 μg/dL), $P = .001$
9 AM serum cortisol	17	659.6 nmol/L (23.9 μg/dL)	361.3 nmol/L (13.1 μg/dL), $P = .0001$	281.3 nmol/L (10.2 μg/dL), $P = .002$
Long-term treatment[d]	38			
Mean CDC	24	451.4 nmol/L (16.4 μg/dL)	339.5 nmol/L (12.3 μg/dL), $P = .07$	366.2 nmol/L (13.3 μg/dL), $P = .35$
9 AM serum cortisol	31	734.2 nmol/L (26.6 μg/dL)	428.2 nmol/L (15.5 μg/dL), $P < .0001$	384.5 nmol/L (13.9 μg/dL), $P < .0001$
Combination therapy	29			
Mean CDC	17	830.8 nmol/L (30.1 μg/dL)	314.2 nmol/L (11.4 μg/dL), $P < .0001$	278.7 nmol/L (10.1 μg/dL), $P < .0001$
9 AM serum cortisol	20	1149 nmol/L (41.6 μg/dL)	522.9 nmol/L (19.0 μg/dL), $P < .0001$	471.9 nmol/L (17.1 μg/dL), $P = .003$

[a] Statistical analysis is compared with the pretreatment value.

[b] Mean cortisol of a CDC.

[c] UFC to the ULN for the assay used.

[d] More than 6 months.

Europe PMC Funders Author Manuscripts

Table 3

Total Daily Dosage of Metyrapone for Patients Treated With a Dose Titration Regimen

	Starting Dose (mg)[a]	Final Dose (mg)[a]
Metyrapone monotherapy (n = 164)	1040, 750, 250–3750	1425, 1500, 500–4000
CD (n = 96)	1020, 750, 250–3000	1380, 1375, 500–3500
EAS (n = 27)	1260, 1000, 500–3750	1990, 1500, 500–3750
Benign adrenal disease (n = 31)	820, 1000, 250–2250	1210, 750, 500–4000
ACC (n = 10)	1230, 1500, 750–2000	1190, 1250, 750–1500
Presurgery (n = 124)	1000, 750, 500–2250	1440, 1500, 500–4000
CD (n = 81)	980, 750, 500–2250	1400, 1500, 500–3500
EAS (n = 11)	1200, 1500, 500–2000	2120, 2250, 500–3750
Benign adrenal disease (n = 25)	880, 750, 500–2250	1230, 1000, 500–4000
ACC (n = 7)	1250, 1500, 750–2000	1080, 1000, 750–1500
Secondary treatment (n = 25)	1300, 1125, 500–3000	1400, 1500, 500–2250
Long-term treatment (>6 mo) (n = 38)	940, 750, 500–3000	1560, 1500, 500–4000

[a]Given in 2–4 divided doses; mean, median, range.